 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.023.805 |
| Chemical and physical data | |
| Formula | C12H18N2 |
| Molar mass | 190.290 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
3-Methylbenzylpiperazine (3-Me-BZP) is a stimulant drug which is a derivative of benzylpiperazine. It has been sold as a designer drug, first being identified in Sweden in February 2012. [1]
The European Coalition for Just and Effective Drug Policies (ENCOD), originally European NGO Council On Drugs and development, is a network of European non-governmental organisations and citizens concerned with the impact of current international drug policies on the lives of the most affected sectors in Europe and the Global South. Since 1994 they have been working to advocate more just and effective drugs control policies, which include an integrated solution for all problems related to the global drugs phenomenon.
Adult lifetime cannabis use by country is the lifetime prevalence of cannabis use among all adults in surveys among the general population. Lifetime prevalence means any use of cannabis during a person's life.
3β-(p-Fluorobenzoyloxy)tropane, (8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 4-fluorobenzoic acid ester, 4-fluorotropacocaine, 3-Pseudotropyl-4-fluorobenzoate, 3-pseudotropyl-4-fluorobenzoate, pFBT) is a tropane derivative drug which acts as a local anaesthetic, having around 30% the stimulant potency of cocaine but around the same potency as a local anaesthetic. It has been investigated as a potential radiolabelled agent for studying receptor binding, but was not adopted for this application. The main application for fluorotropacocaine, however, has been as a designer drug analogue of cocaine, first detected by the EMCDDA in 2008, and subsequently sold as an ingredient of various "bath salt" powder products, usually mixed in combination with other stimulant drugs such as caffeine, dimethocaine, desoxypipradrol or substituted cathinone derivatives.
The drug policy of Portugal, informally called the "drug strategy", was put in place in 2000, and came into effect in July 2001. Its purpose was to reduce the number of new HIV/AIDS cases in the country, as it was estimated around half of new cases came from injection drug use.
Isoethcathinone is a designer drug with purportedly stimulant effects, first encountered in Ireland in 2010 and reported to the EMCDDA new drug monitoring service. It is unclear whether it has desirable pharmacological properties in its own right, or is merely an impurity from the synthesis of ethcathinone.
1-Methylamino-1-(3,4-methylenedioxyphenyl)propane or M-ALPHA is an empathogen, reported by Alexander Shulgin in his book PIHKAL as a positional isomer of MDMA, and subsequently found being sold as a designer drug in the UK in 2010, and reported to the EMCDDA new drug monitoring service. It was described by Alexander Shulgin as similar in action to its demethylated homologue, ALPHA, but with roughly twice the duration and twice the potency.
Benzedrone (4-MBC) is a designer drug which has been found since 2010 as an ingredient in a number of "bath salt" mixes sold as recreational drugs.
4-Acetoxy-MET (4-Acetoxy-N-methyl-N-ethyltryptamine), also known as metacetin or 4-AcO-MET, is a hallucinogenic tryptamine. It is the acetate ester of 4-HO-MET, and a homologue of 4-AcO-DMT. It is a novel compound with very little history of human use. It is sometimes sold as a research chemical by online retailers.
The Mecke reagent is used as a simple spot-test to presumptively identify alkaloids as well as other compounds. It is composed of a mixture of selenous acid and concentrated sulfuric acid, which is dripped onto the substance being tested.
The Froehde reagent is used as a simple spot-test to presumptively identify alkaloids, especially opioids, as well as other compounds. It is composed of a mixture of molybdic acid or a molybdate salt dissolved in hot, concentrated sulfuric acid, which is then dripped onto the substance being tested.
4-Acetyloxy-N,N-diallyltryptamine is a tryptamine derivative. It has been sold as a designer drug, but little other information is available. It was first officially identified in seized drug samples in 2012.
5F-EMB-PINACA is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family that has been sold online as a designer drug.
Methoxypiperamide is a psychoactive drug of the piperazine class that has been sold online as a designer drug. It is the 4-methoxy-α-keto analog of methylbenzylpiperazine.
Cannabis is one of the most popular controlled substances for cultivation and consumption within the country of Belgium. Following global trends, cannabis consumption rates in Belgium have been steadily increasing across the country since the 20th century, and cannabis cultivation continues to expand rapidly on a national scale. Despite significant legal rework of cannabis-related laws since 2010, certain elements of the consumption and cultivation of cannabis are considered to exist within a “legal grey area” of Belgian law. Cannabis is technically illegal in Belgium, but personal possession has been decriminalised since 2003; adults over the age of 18 are allowed to possess up to 3 grams. The legal effort to restrict cultivation and growth has gradually subsided, resulting in an increase of the growth and consumption of cannabis and cannabis-related products.
Bromazolam (XLI-268) is a triazolobenzodiazepine (TBZD) which was first synthesised in 1976, but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified by the EMCDDA in Sweden in 2016. It is the bromo instead of chloro analogue of alprazolam and has similar sedative and anxiolytic effects to it and other benzodiazepines. Bromazolam is a non subtype selective agonist at the benzodiazepine site of GABAA receptors, with a binding affinity of 2.81nM at the α1 subtype, 0.69nM at α2 and 0.62nM at α5.
α-PHiP, is a stimulant drug of the cathinone class that has been sold online as a designer drug. It is a positional isomer of pyrovalerone, with the methyl group shifted from the 4-position of the aromatic ring to the 4-position of the acyl chain. In a classic 2006 study of pyrrolidinyl cathinone derivatives by Meltzer et al. at Organix, the alpha-isobutyl derivative of pyrovalerone, O-2494, was found to have the highest potency in vitro as an inhibitor of the dopamine transporter of the alpha substituted derivatives tested; however, it was not until ten years later in July 2016 that α-PHiP was first identified as a designer drug, when it was reported to the EMCDDA by a forensic laboratory in Slovenia.
4-EA-NBOMe is a substituted amphetamine and 25-NB derivative which has been sold as a designer drug. It was first identified by a forensic laboratory in Germany in 2014, but while its analytical properties and metabolism have been studied, its pharmacology remains unknown.
Cannabis in Tajikistan is illegal with severe penalties for the production, sale, and possession of marijuana for medicinal or recreational purposes. Punishments include up to five years in prison for possession and capital punishment or 25-year sentence for sale.
The Trans-European Drug Information (TEDI) project is a European database compiling information from different drug checking services located on the European continent. The non-governmental organizations feeding into the database are referred to as the TEDI network.
